[DOI] [PubMed] [Google Scholar] 153.Berk M., Dean O.M., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B., Kohlmann K., Jeavons S., Hewitt K., Moss K., Allwang C., Schapkaitz I., Cobb H., Bush A.I., Dodd S., Malhi G.S
(2025) document a case where recognizing the full pattern - skin, ocular, and oral involvement together - was the key to understanding that the condition, while multi-system, was part of a recognized pigmentary entity rather than something sinister
doi: 10.5483/BMBRep.2004.37.2.139
PlexusDx serves all 50 states and requires no health insurance, no membership fee, and no annual enrollment
In fact, only 1.8% of patients discontinued treatment with tirzepatide due to side effects
Tirzepatide Monotherapy as a Safer, Evidence-Backed Alternative Tirzepatide alone has demonstrated superior weight loss outcomes compared to semaglutide and comparable or superior results to older dual-agent regimens in the SURMOUNT clinical trial series